|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||
  American Journal of TransplantationVolume 6 Issue 11, Pages 2680 - 2685 Published Online: 16 Oct 2006 © 2010 American Society of Transplantation and the American Society of Transplant Surgeons
Abstract | References | Full Text: HTML, PDF (Size: 210K) | Related Articles | Citation Tracking  Beneficial Effects of Short-Term Lamivudine Treatment for de novo Hepatitis B Virus Reactivation After Liver Transplantation Copyright 2006 The Authors Journal compilation © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons KEYWORDS Anti-HBc • hepatitis B • hepatitis B immunoglobulin • lamivudine • liver transplantation ABSTRACTClearance of hepatitis B surface antigen (HBsAg) by lamivudine is achieved in only a small proportion of patients with chronic hepatitis B virus (HBV) infection. We investigated the effect of lamivudine on de novo HBV reactivation after living-donor liver transplantation when the number of HBV was expected to be very small. Thirty-eight HBV-naive recipients who received liver grafts from antibodies to core antigen-positive donors receiving hepatitis B immunoglobulin (HBIG) were studied. HBsAg appeared in nine cases (23.7 %) despite receiving HBIG for 12–71 months (mean: 35.1 months) after transplantation. Lamivudine treatment was started in six recipients during the acute phase of HBV reactivation. Five of the six recipients achieved complete clearance of HBsAg in sera at a median of 4.6 months (ranging from 21 to 330 days) after lamivudine administration. Although lamivudine was stopped in four cases, all remained negative for HBsAg. Our findings suggested that short-term lamivudine treatment during acute phase of HBV reactivation could achieve complete clearance of HBsAg in a significant number of liver transplant recipients. Received 11 May 2006, revised 3 July 2006 and accepted for publication 1 August 2006 | 
|
